OptiNose (OPTN) Reports In-Line Q4 EPS, provides guidance

OptiNose (NASDAQ: OPTN) reported Q4 EPS of ($0.09), in-line with the analyst estimate of ($0.09). Revenue for the quarter came in at $19.87 million versus the consensus estimate of $19.23 million.

Corporate Guidance

First Quarter 2024
XHANCE Net RevenueThe Company expects XHANCE net revenues for the first quarter 2024 will be approximately $13.0 million.

Full Year 2024
XHANCE Net Revenue Average Net Revenue per PrescriptionThe Company expects XHANCE average net revenue per prescription will be approximately $220 for full year 2024.

For earnings history and earnings-related data on OptiNose (OPTN) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Medtronic completes $550 million Scientia Vascular acquisition
• UBS Reiterates Neutral Rating on Lennar (LEN) Following Q2 Results